Abstract
Introduction: Tuberous sclerosis (TSC) is an autosomal dominant genetic disorder with a wide range of clinical manifestations. This study aimed to retrospectively analyze the clinical records of TSC patients, focusing on the first onset times and age ranges for various symptoms. Methods: The clinical data of TSC patients were analyzed retrospectively, including general information, clinical manifestations, and treatment plans, with particular attention to the first onset times and age ranges for different symptoms. Results: The study found that 15 patients presented with different types of skin lesions, 13 patients, including 6 with intellectual disabilities, experienced epileptic seizures. Additionally, 14 patients had kidney damage, 6 showed varying degrees of cardiac involvement, and 8 exhibited lung lesions. Conclusion: By integrating the clinical features and imaging characteristics of TSC, multiple manifestations of the disease were identified, providing further clinical evidence for its recognition. This is beneficial for early monitoring and effective disease prevention and improvement.
Journal Section:
Clinical Neurology
References
1.
Pfirmann
P
, Combe
C
, Rigothier
C
. [Tuberous sclerosis complex: a review]
. Rev Med Interne
. 2021
;42
(10
):714
–21
. 2.
Portocarrero
LKL
, Quental
KN
, Samorano
LP
, Oliveira
ZNP
, Rivitti-Machado
M
. Tuberous sclerosis complex: review based on new diagnostic criteria
. Bras Dermatol
. 2018
;93
(3
):323
–31
. 3.
Hong
CH
, Tu
HP
, Lin
JR
, Lee
CH
. An estimation of the incidence of tuberous sclerosis complex in a nationwide retrospective cohort study (1997-2010)
. Br J Dermatol
. 2016
;174
(6
):1282
–9
. 4.
Crino
PB
, Nathanson
KL
, Henske
EP
. The tuberous sclerosis complex
. N Engl J Med
. 2006
;355
(13
):1345
–56
. 5.
Northrup
H
, Aronow
ME
, Bebin
EM
, Bissler
J
, Darling
TN
, de Vries
PJ
, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations
. Pediatr Neurol
. 2021
;123
:50
–66
. 6.
Switon
K
, Kotulska
K
, Janusz-Kaminska
A
, Zmorzynska
J
, Jaworski
J
. Molecular neurobiology of mTOR
. Neuroscience
. 2017
;341
:112
–53
. 7.
Crino
PB
. The pathophysiology of tuberous sclerosis complex
. Epilepsia
. 2010
;51
(Suppl 1
):27
–9
. 8.
Chan
JA
, Zhang
H
, Roberts
PS
, Jozwiak
S
, Wieslawa
G
, Lewin-Kowalik
J
, et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation
. J Neuropathol Exp Neurol
. 2004
;63
(12
):1236
–42
. 9.
Mühlebner
A
, Bongaarts
A
, Sarnat
HB
, Scholl
T
, Aronica
E
. New insights into a spectrum of developmental malformations related to mTOR dysregulations: challenges and perspectives
. J Anat
. 2019
;235
(3
):521
–42
. 10.
Lai
D
, Gade
M
, Yang
E
, Koh
HY
, Lu
J
, Walley
NM
, et al. Somatic variants in diverse genes leads to a spectrum of focal cortical malformations
. Brain
. 2022
;145
(8
):2704
–20
. 11.
Curatolo
P
, Moavero
R
, de Vries
PJ
. Neurological and neuropsychiatric aspects of tuberous sclerosis complex
. Lancet Neurol
. 2015
;14
(7
):733
–45
. 12.
Curatolo
P
, Bombardieri
R
, Jozwiak
S
. Tuberous sclerosis
. Lancet
. 2008
;372
(9639
):657
–68
. 13.
Foiadelli
T
, Santangelo
A
, Costagliola
G
, Costa
E
, Scacciati
M
, Riva
A
, et al. Neuroinflammation and status epilepticus: a narrative review unraveling a complex interplay
. Front Pediatr
. 2023
;11
:1251914
. 14.
Vishwakarma
S
, Singh
S
, Singh
TG
. Pharmacological modulation of cytokines correlating neuroinflammatory cascades in epileptogenesis
. Mol Biol Rep
. 2022
;49
(2
):1437
–52
. 15.
Aronica
E
, Bauer
S
, Bozzi
Y
, Caleo
M
, Dingledine
R
, Gorter
JA
, et al. Neuroinflammatory targets and treatments for epilepsy validated in experimental models
. Epilepsia
. 2017
;58
(Suppl 3
):27
–38
. 16.
Fischborn
SV
, Soerensen
J
, Potschka
H
. Targeting the prostaglandin E2 EP1 receptor and cyclooxygenase-2 in the amygdala kindling model in mice
. Epilepsy Res
. 2010
;91
(1
):57
–65
. 17.
Maroso
M
, Balosso
S
, Ravizza
T
, Iori
V
, Wright
CI
, French
J
, et al. Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice
. Neurotherapeutics
. 2011
;8
(2
):304
–15
. 18.
Rehni
AK
, Singh
TG
. Modulation of leukotriene D4 attenuates the development of seizures in mice
. Prostaglandins Leukot Essent Fatty Acids
. 2011
;85
(2
):97
–106
. 19.
Capal
JK
. Epilepsy and TSC-associated neuropsychiatric disorders
. Pediatr Neurol Briefs
. 2020
;34
:11
. 20.
Northrup
H
, Krueger
DA
; International Tuberous Sclerosis Complex Consensus Group
. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 iinternational tuberous sclerosis complex consensus conference
. Pediatr Neurol
. 2013
;49
(4
):243
–54
. 21.
Scheffer
IE
, Berkovic
S
, Capovilla
G
, Connolly
MB
, French
J
, Guilhoto
L
, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology
. Epilepsia
. 2017
;58
(4
):512
–21
. 22.
Tsang
SH
, Sharma
T
. Tuberous sclerosis
. Adv Exp Med Biol
. 2018
;1085
:205
–7
. 23.
Rosengren
T
, Nanhoe
S
, de Almeida
LGD
, Schönewolf-Greulich
B
, Larsen
LJ
, Hey
CAB
, et al. Mutational analysis of TSC1 and TSC2 in Danish patients with tuberous sclerosis complex
. Sci Rep
. 2020
;10
(1
):9909
. 24.
Au
KS
, Williams
AT
, Roach
ES
, Batchelor
L
, Sparagana
SP
, Delgado
MR
, et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States
. Genet Med
. 2007
;9
(2
):88
–100
. 25.
Kingswood
JC
, d’Augères
GB
, Belousova
E
, Ferreira
JC
, Carter
T
, Castellana
R
, et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients
. Orphanet J Rare Dis
. 2017
;12
(1
):2
. 26.
Orlova
KA
, Crino
PB
. The tuberous sclerosis complex
. Ann N Y Acad Sci
. 2010
;1184
:87
–105
. 27.
Kothare
SV
, Singh
K
, Hochman
T
, Chalifoux
JR
, Staley
BA
, Weiner
HL
, et al. Genotype/phenotype in tuberous sclerosis complex: associations with clinical and radiologic manifestations
. Epilepsia
. 2014
;55
(7
):1020
–4
. 28.
Goh
S
, Butler
W
, Thiele
EA
. Subependymal giant cell tumors in tuberous sclerosis complex
. Neurology
. 2004
;63
(8
):1457
–61
. 29.
Andrade
DM
. Genetic basis in epilepsies caused by malformations of cortical development and in those with structurally normal brain
. Hum Genet
. 2009
;126
(1
):173
–93
. 30.
Holmes
GL
, Stafstrom
CE
; Tuberous Sclerosis Study Group
. Tuberous sclerosis complex and epilepsy: recent developments and future challenges
. Epilepsia
. 2007
;48
(4
):617
–30
. 31.
Nabbout
R
, Belousova
E
, Benedik
MP
, Carter
T
, Cottin
V
, Curatolo
P
, et al. Epilepsy in tuberous sclerosis complex: findings from the TOSCA Study
. Epilepsia Open
. 2019
;4
(1
):73
–84
. 32.
Jansen
FE
, van Huffelen
AC
, Algra
A
, van Nieuwenhuizen
O
. Epilepsy surgery in tuberous sclerosis: a systematic review
. Epilepsia
. 2007
;48
(8
):1477
–84
. 33.
Su
Y
, Wei
Q
, Wan
J
, Li
L
. Tuberous sclerosis complex: early screening and infant outcome in NICU
. J Trop Pediatr
. 2021
;67
(1
):fmab012
. 34.
Curatolo
P
, Jóźwiak
S
, Nabbout
R
; TSC Consensus Meeting for SEGA and Epilepsy Management
. Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations
. Eur J Paediatr Neurol
. 2012
;16
(6
):582
–6
. 35.
de Vries
PJ
, Belousova
E
, Benedik
MP
, Carter
T
, Cottin
V
, Curatolo
P
, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study
. Orphanet J Rare Dis
. 2018
;13
(1
):157
. 36.
Ding
Y
, Wang
J
, Zhou
Y
, Yu
L
, Zhang
L
, Zhou
S
, et al. Quality of life in children with tuberous sclerosis complex: a pediatric cohort study
. CNS Neurosci Ther
. 2021
;27
(3
):280
–8
. 37.
Amin
S
, Lux
A
, Calder
N
, Laugharne
M
, Osborne
J
, O’Callaghan
F
. Causes of mortality in individuals with tuberous sclerosis complex
. Dev Med Child Neurol
. 2017
;59
(6
):612
–7
. 38.
Northrup
H
, Koenig
MK
, Pearson
DA
, Au
KS
. Tuberous sclerosis complex
. In: Adam
MP
, Feldman
J
, Mirzaa
GM
, Pagon
RA
, Wallace
SE
, Bean
LJH
, et al, editors. GeneReviews(®)
. Seattle (WA)
: University of Washington
; 1993
. Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.39.
Martignoni
G
, Bonetti
F
, Pea
M
, Tardanico
R
, Brunelli
M
, Eble
JN
. Renal disease in adults with TSC2/PKD1 contiguous gene syndrome
. Am J Surg Pathol
. 2002
;26
(2
):198
–205
. 40.
Borkowska
J
, Schwartz
RA
, Kotulska
K
, Jozwiak
S
. Tuberous sclerosis complex: tumors and tumorigenesis
. Int J Dermatol
. 2011
;50
(1
):13
–20
. 41.
Lin
L
, Li
X
, Guan
H
, Wang
J
, Tong
X
, Yang
M
, et al. Renal function, complications, and outcomes of a reduction in tumor size after transarterial embolization for renal angiomyolipomas: a meta-analysis
. J Int Med Res
. 2019
;47
(4
):1417
–28
. 42.
Teng
JM
, Cowen
EW
, Wataya-Kaneda
M
, Gosnell
ES
, Witman
PM
, Hebert
AA
, et al. Dermatologic and dental aspects of the 2012 international tuberous sclerosis complex Consensus statements
. JAMA Dermatol
. 2014
;150
(10
):1095
–101
. 43.
Pfirmann
P
, Aupy
J
, Jambon
E
, Idier
L
, Prezelin-Reydit
M
, Fermis
M
, et al. Description of a multidisciplinary model of care in a French cohort of adult patients with tuberous sclerosis complex
. J Med Genet
. 2021
;58
(1
):25
–31
. 44.
Tyburczy
ME
, Wang
JA
, Li
S
, Thangapazham
R
, Chekaluk
Y
, Moss
J
, et al. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex
. Hum Mol Genet
. 2014
;23
(8
):2023
–9
. 45.
Nguyen
QBD
, DarConte
MD
, Hebert
AA
. The cutaneous manifestations of tuberous sclerosis complex
. Am J Med Genet C Semin Med Genet
. 2018
;178
(3
):321
–5
. 46.
Adriaensen
ME
, Schaefer-Prokop
CM
, Duyndam
DA
, Zonnenberg
BA
, Prokop
M
. Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex
. Clin Radiol
. 2011
;66
(7
):625
–8
. 47.
Cudzilo
CJ
, Szczesniak
RD
, Brody
AS
, Rattan
MS
, Krueger
DA
, Bissler
JJ
, et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis
. Chest
. 2013
;144
(2
):578
–85
. 48.
Henske
EP
, Jóźwiak
S
, Kingswood
JC
, Sampson
JR
, Thiele
EA
. Tuberous sclerosis complex
. Nat Rev Dis Primers
. 2016
;2
:16035
. 49.
Taveira-DaSilva
AM
, Jones
AM
, Julien-Williams
P
, Yao
J
, Stylianou
M
, Moss
J
. Severity and outcome of cystic lung disease in women with tuberous sclerosis complex
. Eur Respir J
. 2015
;45
(1
):171
–80
. 50.
Ebrahimi-Fakhari
D
, Mann
LL
, Poryo
M
, Graf
N
, von Kries
R
, Heinrich
B
, et al. Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study
. Orphanet J Rare Dis
. 2018
;13
(1
):117
. 51.
Silva-Sánchez
MP
, Alvarado-Socarras
JL
, Castro-Monsalve
J
, Meneses
KM
, Santiago
J
, Prada
CE
. Everolimus for severe arrhythmias in tuberous sclerosis complex related cardiac rhabdomyomas
. Am J Med Genet
. 2021
;185
(5
):1525
–31
. 52.
Jülich
K
, Sahin
M
. Mechanism-based treatment in tuberous sclerosis complex
. Pediatr Neurol
. 2014
;50
(4
):290
–6
. 53.
French
JA
, Lawson
JA
, Yapici
Z
, Ikeda
H
, Polster
T
, Nabbout
R
, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
. Lancet
. 2016
;388
(10056
):2153
–63
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
